OnKure Therapeutics (OKUR)

Executive Summary

OnKure Therapeutics is a clinical-stage biopharmaceutical company focused on developing next-generation precision oncology therapies, particularly small molecules targeting genetically defined cancers. The company's lead asset, OKI-219, is a potential best-in-class PI3Kα pan-mutant selective inhibitor currently in a Phase 1 trial (NCT06239467) for advanced solid tumors with PI3K gene mutations, including breast cancer. This tumor-agnostic approach aims to treat patients based on molecular drivers rather than tissue of origin. Additionally, OnKure has an early-stage pipeline including OKI-179, an HDAC inhibitor previously studied in RAS-mutant tumors, though its development status is unclear after completed trials. The company also holds legacy assets like REN001 for metabolic disorders, but these are not core to the oncology focus. With a market cap of approximately $207M, OnKure is at an early inflection point, relying on the successful advancement of OKI-219 to drive value.

Upcoming Catalysts (preview)

• Q3 2026OKI-219 Phase 1 preliminary efficacy and safety data readout55% success
• Q1 2027Initiation of OKI-219 expansion cohorts or Phase 2 in a specific indication40% success
• H2 2026Potential out-licensing or partnership for non-core assets (e.g., REN001 or OKI-179)25% success